20cm速递丨科创创新药ETF国泰（589720）涨超3.6%，创新与出海主线获市场关注

Core Viewpoint - The pharmaceutical sector in China is expected to experience a strong rebound by 2025, driven by AI and innovative drugs, reflecting a qualitative leap in China's innovation capabilities and the realization of overseas expansion logic [1] Group 1: Market Trends - The ETF for innovative drugs, Guotai (589720), rose over 3.6%, indicating market interest in innovation and overseas expansion [1] - The chemical pharmaceutical sector is showing signs of recovery following policy reforms [1] Group 2: Investment Opportunities - The transition of innovative drugs from narrative to realization is marked by record transaction amounts, supported by comprehensive domestic policies [1] - The CRO/CDMO industry is experiencing a resonance of domestic and international demand, with a recovery in global investment and financing leading to increased orders [1] - The pharmaceutical sector is anticipated to benefit from a "Davis Double Play," with investment strategies in 2026 focusing on innovative growth and turnaround logic [1] Group 3: Performance Metrics - From September 24, 2024, to October 31, 2025, during the market rebound, the growth rates for the innovative drug indices were 143.70% for the Sci-Tech Innovation Drug Index and 135.34% for the Hang Seng Hong Kong Stock Connect Innovative Drug Index [1] - The Sci-Tech Innovation Drug Index may provide better exposure to the volatility of the Sci-Tech Innovation Board when market risk appetite increases [1]